GS
GPCR icon

GTS Securities’s Structure Therapeutics GPCR Stock Holding History

GTS Securities’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,000
Closed -$263K – 2408
2024
Q3 		$263K Buy
6,000
+500
+9% +$19.3K ﹤0.01% 3411
2024
Q2 		$216K Sell
5,500
-1,100
-17% -$45.2K ﹤0.01% 3382
2024
Q1 		$283K Buy
+6,600
New +$278K ﹤0.01% 3040

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GTS Securities's GPCR Position: Q3 2024 in Review

GTS Securities sold out of Structure Therapeutics (GPCR) in Q3 2024, closing a stake of 8,332 shares — an estimated $322K sold.

GTS Securities first reported a position in GPCR in Q2 2024 and held it in 1 quarter. The position peaked at $327K in Q2 2024. 160 funds tracked by Wall St. Rank hold GPCR as of Q3 2024.

  • GTS Securities reported no remaining Structure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • GTS Securities sold 8,332 Structure Therapeutics shares in Q3 2024, an estimated $322K.
  • GTS Securities first reported a position in Structure Therapeutics in Q2 2024 and held it in 1 quarter.
  • GTS Securities's Structure Therapeutics position peaked at $327K in Q2 2024.
  • 160 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.